Taiwanese Companies Eye Puerto Rico Market

Taiwanese biopharmaceutical firm PharmaEssentia Corporation is establishing a new manufacturing subsidiary in Puerto Rico as part of a broader strategic effort by Taiwanese companies to expand their North American footprint.

The company will invest $46 million to launch the facility, which is intended to support U.S. Manufacturing, supply security, and the long-term growth of its product BESREMi (ropeginterferon alfa-2b), according to company announcements and reports from the Puerto Rico Department of Economic Development and Commerce (DDEC).

Strategic Shift in Supply Chains

The move comes amid shifting global supply chains and evolving trade policies. Recent reporting indicates that Taiwanese pharmaceutical firms are accelerating their push into North America following the imposition of 100% pharmaceutical tariffs by the U.S. Government under the Trump administration.

Puerto Rico is viewed by these firms as a strategic pharma hub due to its existing infrastructure and tax-advantaged environment, which allows companies to establish a presence within the U.S. Regulatory and trade framework while leveraging the island’s specialized workforce.

PharmaEssentia, which is headquartered in Taiwan, specializes in the development of novel biologics for hematology and oncology. The establishment of a wholly owned subsidiary in Puerto Rico allows the firm to mitigate geopolitical risks and policy headwinds affecting direct exports from Asia to the United States.

Investment and Operational Timeline

The $46 million investment was formalized with the support of the Puerto Rican government. Governor Jenniffer González Colón and the DDEC have highlighted the project as a key component of the island’s economic development strategy to attract high-tech manufacturing.

PharmaEssentia projects that operations at the Puerto Rico facility will begin in 2027. The facility is expected to focus on the production of biologics, strengthening the supply chain for the U.S. Market.

Broader Economic Context

The interest from Taiwan extends beyond the pharmaceutical sector. There is growing institutional interest in Puerto Rico’s potential for semiconductor and chip manufacturing, as Taiwan seeks to diversify its production bases and align with U.S. Efforts to secure critical technology supply chains.

By integrating into the Puerto Rican ecosystem, Taiwanese firms can navigate the complexities of U.S. Trade law more effectively. The island’s long history as a center for pharmaceutical manufacturing provides a ready-made cluster of suppliers and skilled labor that reduces the entry barrier for foreign biopharmaceutical companies.

This trend reflects a wider movement where Taiwanese firms are utilizing U.S. Acquisitions and the establishment of Caribbean-based operations to ensure market access and operational stability in the face of volatile international trade relations.